Key result
Raising HDL-C holds promise for coronary risk reduction, but definitive outcome trials are needed.
No takes yet. Share an insight, caveat, or question.
While epidemiological evidence supports an inverse association between HDL-C and coronary heart disease risk, the clinical benefit of HDL-raising therapies awaits confirmation from large outcome trials.
Natarajan et al. (2010) conducted a review in Coronary heart disease. HDL-C targeted therapies was evaluated. Raising HDL-C levels holds promise for reducing coronary heart disease risk, though large clinical outcomes trials are needed to define the clinical role of HDL-targeted therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: